[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100623025":3},{"organization":4,"armGroups":7,"interventions":21,"overallOfficials":27,"centralContacts":36,"locations":42,"responsibleParty":58,"collaborators":27,"id":60,"slug":61,"hasResults":62,"nctId":63,"briefTitle":64,"officialTitle":65,"acronym":27,"eligibilityCriteria":66,"healthyVolunteers":62,"sex":67,"minAge":68,"maxAge":27,"enrollmentInfo":69,"targetDuration":27,"studyType":72,"phases":73,"briefSummary":75,"conditions":76,"keywords":27,"overallStatus":79,"whyStopped":27,"lastUpdateSubmitDate":80,"lastUpdatePostDateStruct":81,"startDateStruct":84,"completionDateStruct":86,"leadSponsor":88,"locationsCount":89},{"fullName":5,"class":6},"Institute of Liver and Biliary Sciences, India","OTHER",[8,15],{"label":9,"type":10,"description":11,"interventionNames":12},"Standard Medical Treatment (SMT)","ACTIVE_COMPARATOR","Control arm : Participants in this arm will receive Placebo with Standard Medical Treatment (SMT).",[13,14],"Other: Placebo","Other: Standard medical treatment",{"label":16,"type":17,"description":18,"interventionNames":19},"Semaglutide with Standard Medical Treatment","EXPERIMENTAL","Semaglutide with Standard Medical Treatment: Participants in this arm will receive Standard medical treatment and oral semaglutide starting from 3mg dose daily that gradually increases upto 14mg dose daily for 6 months.",[20,14],"Drug: Semaglutide Oral Tablet",[22,28,32],{"type":23,"name":24,"description":25,"armGroupLabels":26,"otherNames":27},"DRUG","Semaglutide Oral Tablet","GLP1-R agonists GLP1-R agonists (GLP1-RAs) are novel potent antidiabetic agents with proven efficacy in reducing major adverse cardiovascular events. Besides their glucose-lowering action, their beneficial hepatic effects may be related to the influence on the AMPK\u002FmTOR pathway. Semaglutide was associated with significant decreases in body weight, alanine aminotransferase, liver steatosis, and stiffness.GLP1-RAs may also improve histologic features on NAFLD, such as liver fat deposition, steatohepatitis, and fibrosis. GLP1-RAs have shown benefits in preventing the development or halting the progression of CKD. It also promotes antioxidative and anti-inflammatory actions may be among the determining factors in this renoprotective effect, together with weight loss, blood pressure, and glucose-lowering.",[16],null,{"type":6,"name":29,"description":30,"armGroupLabels":31,"otherNames":27},"Placebo","Placebo will be given in the same manner.",[9],{"type":6,"name":33,"description":34,"armGroupLabels":35,"otherNames":27},"Standard medical treatment","Standard medical treatment-\n\n1. Lifestyle first - weight loss , caloric restriction, increased aerobic + resistance exercise, treat obesity and metabolic syndrome.\n2. Optimize blood-pressure control and use RAAS blockade when indicated (ACE inhibitor or ARB) to reduce albuminuria and slow CKD progression .\n3. Treat dysglycaemia and favour drug classes with kidney + liver benefit when appropriate\n\n   * SGLT2 inhibitors (dapagliflozin, empagliflozin, canagliflozin) - recommended for people with T2D + CKD\n   * GLP-1 receptor agonists (e.g., semaglutide)\n4. Lipid management \u002F statins - treat according to CV risk\n5. Consider established liver-directed agents when appropriate\n6. Pioglitazone (thiazolidinedione) and vitamin-E\n7. Standard CKD supportive care - salt and fluid management, correction of metabolic acidosis, anaemia and mineral bone abnormalities as per CKD stage; immunize and address CV risk factors aggressively\n8. Avoid hepatotoxic drugs \u002F review medications",[16,9],[37],{"name":38,"role":39,"phone":40,"phoneExt":27,"email":41},"Dr Chandani Bhagat, DM","CONTACT","01146300000","chandani.bhagat@gmail.com",[43],{"facility":44,"status":27,"city":45,"state":46,"zip":47,"country":48,"countryCode":49,"cosmosGeoPoint":50,"geoPoint":55,"contacts":56},"Institute of Liver and Biliary Sciences","New Delhi","National Capital Territory of Delhi","110070","India","IN",{"type":51,"coordinates":52},"Point",[53,54],77.2148,28.62137,{"lat":54,"lon":53},[57],{"name":38,"role":39,"phone":40,"phoneExt":27,"email":41},{"type":59,"investigatorFullName":27,"investigatorTitle":27,"investigatorAffiliation":27,"oldNameTitle":27,"oldOrganization":27},"SPONSOR","100623025","pathogenesis-of-chronic-kidney-disease-associated-with-metabolic-dysfunction--associated-fatty-liver-disease-mafld-and-treatment-response-of-oral-semaglutide-100623025",false,"NCT07391267","Pathogenesis of Chronic Kidney Disease Associated With Metabolic Dysfunction- Associated Fatty Liver Disease (MAFLD) and Treatment Response of Oral Semaglutide.","Pathogenesis of Chronic Kidney Disease Associated With Metabolic Dysfunction- Associated Fatty Liver Disease (MAFLD) and Treatment Response of Oral Semaglutide - a Randomized Controlled Trial.","Inclusion Criteria:\n\n* 1.Age above or equal to 18 years at the time of signing informed consent. 2.Diagnosed with type 2 diabetes mellitus 3.HbA1c less than or equal to 10% (less than or equal to 86 mmol\u002Fmol) 4.Renal impairment defined either by:\n* serum creatinine-based eGFR greater than or equal to 50 and less than or equal to 75 mL\u002Fmin\u002F1.73 m\\^2 (CKD-EPI) and UACR greater than 300 and less than 5000 mg\u002Fg or\n* serum creatinine-based eGFR greater than or equal to 25 and less than 50 mL\u002Fmin\u002F1.73 m\\^2 (CKD-EPI) and UACR greater than 100 and less than 5000 mg\u002Fg 5.Treatment with maximum labelled or tolerated dose of a reninangiotensin-aldosterone system (RAAS) blocking agent including an angiotensin converting enzyme (ACE) inhibitor or an angiotensin II receptor blocker (ARB), unless such treatment is contraindicated or not tolerated. Treatment dose must be stable for at least 4 weeks prior to the date of the laboratory assessments used for determination of the inclusion criteria for renal impairment and kept stable until screening.\n\nExclusion Criteria:\n\n1. Documented causes of chronic liver disease other than non-alcoholic fatty liver disease (NAFLD)\n2. Positive HBsAg, positive anti-HIV, positive HCV RNA at screening (V2A) or any known presence of HCV RNA or HBsAg within 2 years of screening (V2A).\n3. Presence or history of ascites, variceal bleeding, hepatic encephalopathy, spontaneous bacterial peritonitis or liver transplantation at randomisation.\n4. Known or suspected excessive consumption of alcohol (greater than 20 g\u002Fday for women or greater than 30 g\u002Fday for men) or alcohol dependence (assessed by the Alcohol Use Disorders Identification Test (AUDIT questionnaire)).\n5. Treatment with vitamin E (at doses greater than or equal to 800 IU\u002Fday) or pioglitazone or medications approved for treatment of NASH which has not been at a stable dose in the period from 90 days prior to the screening visit (V2A). In addition, for subjects with historical liver biopsies taken more than 90 days prior to screening, treatment should be at a stable dose from time of biopsy until screening.\n6. Treatment with GLP-1 RAs in the period from 90 days prior to the screening visit (V2A). In addition, for subjects with historical liver biopsies taken more than 90 days prior to screening, any treatment with GLP-1 RAs from time of biopsy until screening (V2A).\n7. Treatment with glucose-lowering agent(s) (other than GLP-1 RAs), lipid-lowering medication or weight loss medication not stable in the opinion of the investigator in the period from 90 days prior to the screening visit (V2A). In addition, for subjects with historical liver biopsies taken more than 90 days prior to screening, treatment should be at a stable dose in the opinion of the investigator from time of biopsy until screening.\n8. Congenital or hereditary kidney diseases including polycystic kidney disease, autoimmune kidney diseases including glomerulonephritis or congenital urinary tract malformations\n9. Myocardial infarction, stroke, hospitalisation for unstable angina pectoris or transient ischaemic attack within 60 days prior to the day of screening.\n10. Presently classified as being in New York Heart Association (NYHA) Class IV heart failure\n11. Planned coronary, carotid or peripheral artery revascularisation\n12. Current (or within 90 days) chronic or intermittent haemodialysis or peritoneal dialysis 13 Uncontrolled and potentially unstable diabetic retinopathy or maculopathy. Verified by a fundus examination performed within the past 90 days prior to screening or in the period between screening and randomisation. Pharmacological pupildilation is a requirement unless using a digital fundus photography camera specified for non-dilated examination.\n\n    \\-","ALL","18 Years",{"count":70,"type":71},90,"ESTIMATED","INTERVENTIONAL",[74],"NA","This project aims to investigate how Chronic Kidney Disease (CKD) develops and progresses in patients who also have Non-Alcoholic Fatty Liver Disease (NAFLD) and to evaluate whether oral semaglutide (a GLP-1 receptor agonist) can slow or prevent this progression.\n\nNAFLD and CKD frequently coexist due to shared mechanisms such as insulin resistance, inflammation, oxidative stress, dyslipidemia, and metabolic syndrome. Because of these overlapping pathways, a single therapy targeting both organs may offer major benefits.\n\nSemaglutide is known to reduce liver fat, improve inflammation and fibrosis, promote weight loss, and provide renal protection. This project will test whether adding oral semaglutide to standard care leads to better kidney and liver outcomes than standard care alone.\n\nThe study is designed as a randomised controlled trial conducted at ILBS, enrolling adults having NAFLD with CKD (with specific eGFR and albuminuria criteria). Participants will be followed for 2 years, with regular assessment of kidney function (eGFR, ACR), liver health (FibroScan, ALT\u002FAST), metabolic parameters, and cardiovascular outcomes.\n\nA parallel animal study in mice with diet-induced fatty liver disease will validate mechanistic findings through liver and kidney histology, gene expression, metabolic tests, and biochemical markers after semaglutide treatment.\n\nExpected outcome: To demonstrate that semaglutide slows CKD progression and improves NAFLD, supporting its use as a therapeutic option for patients with coexisting both conditions.",[77,78],"Chronic Kidney Diseases","MAFLD","NOT_YET_RECRUITING","2026-01-29",{"date":82,"type":83},"2026-02-05","ACTUAL",{"date":85,"type":71},"2026-02-01",{"date":87,"type":71},"2028-12-31",{"name":5,"class":6},1]